Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2011

01-06-2011 | Original Paper

Golimumab and malignancies: true or false association?

Authors: Ines Zidi, Aicha Bouaziz, Wissem Mnif, Aghleb Bartegi, Nidhal Ben Amor

Published in: Medical Oncology | Issue 2/2011

Login to get access

Abstract

Malignancy is one of the comorbidities linked to golimumab, a biological TNF-α blocker. In this systematic review and meta-analysis, we searched different databases and analyzed original publications to elucidate the remaining open question about the real association of malignancies with golimumab therapy. The most frequent cancer in patients treated with golimumab, in association or not with methotrexate, is the lung adenocarcinoma. However, lymphoma is not very commonly represented in these patients. We show that there is no major and evident risk of malignancies associated with golimumab in current scientific literature. An increased risk of malignancies may be associated with golimumab, but this warrants further clinical confirmation. Also, this risk mentioned in different studies must be taken with caution because of number of limits and biases.
Literature
1.
Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004;140:218–25.PubMedCrossRef
2.
Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum. 2008;39:132–43.PubMedCrossRef
3.
Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 2009;22:418–30.PubMedCrossRef
4.
Ferrandiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol. 2010;28:81–7.PubMedCrossRef
5.
Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis. 2008;67:1497–8.PubMedCrossRef
6.
7.
Hutas G. Golimumab, a fully human monoclonal antibody against TNF-alpha. Curr Opin Mol Ther. 2008;10:393–406.PubMed
8.
9.
Kay J, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum. 2008;58:964–75.PubMedCrossRef
10.
Emery P, et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of Golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–83.PubMedCrossRef
11.
Keystone EC, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy : the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–96.PubMedCrossRef
12.
Smolen JS, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210–21.PubMedCrossRef
13.
14.
Oldfield V, Plosker GL. Golimumab in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Biodrugs. 2009;23(2):125–35.PubMedCrossRef
15.
Kavanaugh A, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in Psoriatic Arthritis : twenty-Four-Week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–86.PubMedCrossRef
16.
Xu Z, et al. Population pharmacokinetics of Golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49:1056–70.PubMedCrossRef
17.
Inman RD, et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis: results of a randomized, double-Blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12.PubMedCrossRef
18.
19.
Gaga M, Zervas E, Chanez P. Update on severe asthma: what we know and what we need. Eur Respir Rev. 2009;18:58–65.PubMedCrossRef
20.
Wenzel SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549–58.PubMedCrossRef
21.
22.
Shealy D, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF alpha. Ann Rheum Dis. 2007;66 (Suppl 2):ii151.
23.
24.
Saraceno R, Chimenti S. How to manage infections in the era of biologics? Dermatol Ther. 2008;21:180–6.PubMedCrossRef
25.
Hussar DA. Newdrugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine. J Am Pharm Assoc. 2009;49(4):570–4.CrossRef
26.
Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.PubMedCrossRef
27.
Setoguchi S, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2757–64.PubMedCrossRef
28.
Dewan P, et al. Melanoma in patients with rheumatoid arthritis treated with antitumour necrosis factor: cause or coincidence? Report of two cases. Br J Dermatol. 2009;161:1412–4.PubMedCrossRef
29.
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 2007;56(9):2886–95.PubMedCrossRef
30.
Kornbluth A. Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998;4:328–9.PubMedCrossRef
31.
Mahe E, et al. CD30 + T-cell lymphoma in patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149:170–3.PubMedCrossRef
32.
Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica. 1983;167:260–1.PubMedCrossRef
33.
Salliot C, van der Heijde D. Methotrexate monotherapy in rheumatoid arthritis patients. A systematic literature research. Ann Rheumatic Dis. 2009;68:1100–4.CrossRef
34.
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum. 2004;50:1740–51.PubMedCrossRef
35.
Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may ba associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.PubMedCrossRef
36.
Askling J, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–6.PubMedCrossRef
37.
Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22:56–60.PubMedCrossRef
38.
Soriano ER, Rosa J. Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep. 2009;11:270–7.PubMedCrossRef
39.
Antoni CE, et al. Two-year efficacy and safety of Infliximab treatment in patients with active psoriatic arthritis: findings of the Inliximab Multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol. 2008;35:869–76.PubMed
40.
Mease PJ, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721.
41.
Mease PJ, et al. Adalimumab for long-term treatment of psoriasis arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702–9.PubMedCrossRef
42.
Davis JC, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis : a randomized, controlled trial. Arthritis Rheum. 2003;48:3230–6.PubMedCrossRef
43.
Van der Heijde D, et al. Efficacy and safety of Infliximab in patients with ankylosing spondylitis: results of a randomized, placebo controlled-trial (ASSERT). Arthritis Rheum. 2005;52:582–91.PubMedCrossRef
44.
Van der Heijde D, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46.PubMedCrossRef
45.
Zhou H, et al. Pharmacokinetics and safety of Golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with Rheumatoid Arthritis. J Clin Pharmacol. 2007;47:383–96.PubMedCrossRef
46.
47.
48.
Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy- a critical review. Can J Gastroenterol. 2001;15(6):376–84.PubMed
49.
50.
51.
Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28:88–92.PubMedCrossRef
52.
53.
Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis. 2008;67:iii2–iii25.
54.
Mariette X, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate : a 3-year prospective study in France. Blood. 2002;99(11):3909–15.PubMedCrossRef
55.
Stone JH, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept trial. Arthritis Rheum. 2006;54(5):1608–18.PubMedCrossRef
56.
Van den Born BE, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1930–7.CrossRef
57.
Kremer J, et al. Golimumab, a new human anti-TNFα antibody, administered intravenously in patients with active rheumatoid arthritis: 48-week efficacy and safety results of a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010. doi:10.​1002/​art.​27348.
Metadata
Title
Golimumab and malignancies: true or false association?
Authors
Ines Zidi
Aicha Bouaziz
Wissem Mnif
Aghleb Bartegi
Nidhal Ben Amor
Publication date
01-06-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9490-7

Other articles of this Issue 2/2011

Medical Oncology 2/2011 Go to the issue

Original Paper

Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death

Original Paper

Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma

Original Paper

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer

Original Paper

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate

Original Paper

Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study

Original paper

Reproductive factors associated with breast cancer risk in northern Iran
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits